295 related articles for article (PubMed ID: 22875942)
1. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
[TBL] [Abstract][Full Text] [Related]
2. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
4. Suppression of protein aggregation by chaperone modification of high molecular weight complexes.
Labbadia J; Novoselov SS; Bett JS; Weiss A; Paganetti P; Bates GP; Cheetham ME
Brain; 2012 Apr; 135(Pt 4):1180-96. PubMed ID: 22396390
[TBL] [Abstract][Full Text] [Related]
5. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
[TBL] [Abstract][Full Text] [Related]
6. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein.
Nucifora LG; Burke KA; Feng X; Arbez N; Zhu S; Miller J; Yang G; Ratovitski T; Delannoy M; Muchowski PJ; Finkbeiner S; Legleiter J; Ross CA; Poirier MA
J Biol Chem; 2012 May; 287(19):16017-28. PubMed ID: 22433867
[TBL] [Abstract][Full Text] [Related]
8. siRNA screen identifies QPCT as a druggable target for Huntington's disease.
Jimenez-Sanchez M; Lam W; Hannus M; Sönnichsen B; Imarisio S; Fleming A; Tarditi A; Menzies F; Dami TE; Xu C; Gonzalez-Couto E; Lazzeroni G; Heitz F; Diamanti D; Massai L; Satagopam VP; Marconi G; Caramelli C; Nencini A; Andreini M; Sardone GL; Caradonna NP; Porcari V; Scali C; Schneider R; Pollio G; O'Kane CJ; Caricasole A; Rubinsztein DC
Nat Chem Biol; 2015 May; 11(5):347-354. PubMed ID: 25848931
[TBL] [Abstract][Full Text] [Related]
9. Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.
Safren N; El Ayadi A; Chang L; Terrillion CE; Gould TD; Boehning DF; Monteiro MJ
PLoS One; 2014; 9(1):e87513. PubMed ID: 24475300
[TBL] [Abstract][Full Text] [Related]
10. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
12. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
[TBL] [Abstract][Full Text] [Related]
13. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
14. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic cellular phenotypes are germline transmissible in a transgenic primate model of Huntington's disease.
Putkhao K; Kocerha J; Cho IK; Yang J; Parnpai R; Chan AW
Stem Cells Dev; 2013 Apr; 22(8):1198-205. PubMed ID: 23190281
[TBL] [Abstract][Full Text] [Related]
16. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
[TBL] [Abstract][Full Text] [Related]
17. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
18. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
[TBL] [Abstract][Full Text] [Related]
19. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
[TBL] [Abstract][Full Text] [Related]
20. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice.
Lee J; Kosaras B; Del Signore SJ; Cormier K; McKee A; Ratan RR; Kowall NW; Ryu H
Acta Neuropathol; 2011 Apr; 121(4):487-98. PubMed ID: 21161248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
